RVPHREVIVA PHARMACEUTICALS HOLD...

Nasdaq revivapharma.com


$ 3.06 $ 0.16 (5.52 %)    

Tuesday, 30-Apr-2024 13:28:39 EDT
QQQ $ 427.16 $ -5.10 (-1.18 %)
DIA $ 379.64 $ -2.58 (-0.68 %)
SPY $ 504.50 $ -3.41 (-0.67 %)
TLT $ 88.24 $ -0.23 (-0.26 %)
GLD $ 212.19 $ -1.77 (-0.83 %)
$ 2.9
$ 2.98
$ 0.00 x 0
$ 3.13 x 100
$ 2.98 - $ 3.07
$ 2.67 - $ 9.25
114,659
na
15.95M
$ -0.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-15-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-30-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-15-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 05-17-2021 03-31-2021 10-Q
13 03-22-2021 12-31-2020 10-K
14 01-14-2021 11-30-2020 10-Q
15 10-14-2020 08-31-2020 10-Q
16 07-07-2020 05-31-2020 10-Q
17 05-04-2020 02-29-2020 10-K
18 01-10-2020 11-30-2019 10-Q
19 10-08-2019 08-31-2019 10-Q
20 07-03-2019 05-31-2019 10-Q
21 05-22-2019 02-28-2019 10-K
22 01-09-2019 11-30-2018 10-Q
23 10-11-2018 08-31-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-reviva-pharmaceuticals-maintains-20-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains ...

 benchmark-reiterates-speculative-buy-on-reviva-pharmaceuticals-maintains-17-price-target

Benchmark analyst Bruce Jackson reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Speculative Buy and maintains $17 pri...

 reviva-pharmaceuticals-q4-eps-035-misses-032-estimate

Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate...

 reviva-to-present-recover-phase-3-clinical-trial-data-for-brilaroxazine-in-schizophrenia-at-the-ascpt-2024-annual-meeting

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical co...

 hc-wainwright--co-reiterates-buy-on-reviva-pharmaceuticals-maintains-20-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains ...

 hc-wainwright--co-reiterates-buy-on-reviva-pharmaceuticals-maintains-20-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains ...

 reviva-to-host-kol-event-to-discuss-topline-data-from-phase-3-recover-trial-of-brilaroxazine-in-schizophrenia

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical co...

 reviva-provides-corporate-and-program-updates-and-highlights-key-upcoming-milestones

– Schizophrenia late-stage clinical program advances with positive topline Phase 3 data, successful ongoing enrollment in open ...

 hc-wainwright--co-reiterates-buy-on-reviva-pharmaceuticals-maintains-20-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains ...

 reviva-pharmaceuticals-q3-eps-044-misses-037-estimate

Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate...

 hc-wainwright--co-maintains-buy-on-reviva-pharmaceuticals-raises-price-target-to-20

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and raises the ...

 analyst-assessment-on-reviva-pharmaceuticals-positive-schizophrenia-trial-data---sees-more-than-200-upside-in-stock

Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) shares are surging after the company released topline results of its pivotal...

 roth-mkm-reiterates-buy-on-reviva-pharmaceuticals-maintains-12-price-target

Roth MKM analyst Scott Henry reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $12 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION